/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
C4 Therapeutics (CCCC) has never paid a dividend. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.
No. C4 Therapeutics (CCCC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
It largely does not. C4 Therapeutics pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
Not currently. C4 Therapeutics's free cash flow is negative at -$96 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with C4 Therapeutics.
SourceDividend analysis computed from the 10-Q filed 12 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 24 Jun 2026. How this is calculated.
Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.